Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

NCT01455090 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: BMS-650032
DRUG: BMS-790052
DRUG: BMS-791325
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb